| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director | Director, 10% Owner
7 companies
Patrick G Enright is Director, 10% Owner at MANE and has filed Form 4s across 7 companies. Patrick G Enright's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $301.5M at current prices.
Historically, Patrick G Enright's trades have earned a strong insider score of 71/100 across 13 rated trades. Over a 12-month horizon, 70.0% of those trades were profitable, with an average 12-month return of +11.7%.
The biggest single holding is MANE (~$274.4M) as Director, 10% Owner. Net of sales, the MANE filings show accumulation of 1,075,000 shares.
Patrick G Enright has 57 Form 4 filings on record from March 2015 to August 2026, across 7 companies: Director at Jazz Pharmaceuticals (JAZZ), 2016–2026; Director at Zenas BioPharma (ZBIO), 2024–2026; Director at BioAge Labs (BIOA), 2024–2026, and 4 more.
The 140 reported transactions were 66 open-market sales, 21 option or other derivative awards, 14 open-market purchases and 12 stock awards, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 9 purchases worth about $67.7M and 22 sales worth about $113.9M.
The largest open-market purchase was 1,075,000 shares of MANE at an average $17.00 on February 5, 2026, about $18.3M.
The largest open-market sale was 500,000 shares of ESPR at an average $111.66 on March 19, 2015, about $55.8M.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Feb 5, 2026 | MANE Veradermics, Incorporated | Director, 10% Owner | Buy | 1,075,000 | $17.00 | $18,275,000.00 | +109.9% | +195.4% | - | |
| Dec 11, 2025 | VERA Vera Therapeutics, Inc. | Director | Buy | 5,882 | $42.50 | $249,985.00 | New | -8.6% | - | |
| Oct 9, 2025 | ZBIO Zenas Biopharma, Inc. | Director | Buy | 117,255 | $19.19 | $2,250,026.50 | -111.4% | -40.5% | -1.8% | |
| Jun 24, 2025 | VERA Vera Therapeutics, Inc. | Director | Buy | 250,000 | $21.11 | $5,277,311.42 | +7.5% | +15.6% | - | |
| Sep 27, 2024 | BIOA Bioage Labs, Inc. | Director | Buy | 400,000 | $18.00 | $7,200,000.00 | +30.5% | -72.0% | -74.2% | |
| Sep 16, 2024 | ZBIO Zenas Biopharma, Inc. | Director | Buy | 440,000 | $17.00 | $7,480,000.00 | +131.5% | -51.2% | +1.5% | |
| Aug 14, 2023 | JAZZ Jazz Pharmaceuticals Plc | Director | Sell | 1,241 | $138.16 | $171,454.70 | -5.6% | -12.9% | -20.2% | |
| Feb 6, 2023 | VERA Vera Therapeutics, Inc. | Director, 10% Owner | Buy | 1,714,285 | $7.00 | $11,999,995.00 | New | +8.5% | +445.9% | |
| Nov 22, 2022 | JAZZ Jazz Pharmaceuticals Plc | Director | Sell | 6,974 | $150.45 | $1,049,264.13 | -100% | -5.3% | -20.6% | |
| Aug 8, 2022 | JAZZ Jazz Pharmaceuticals Plc | Director | Sell | 1,089 | $152.33 | $165,883.45 | -4.3% | -5.7% | -14.2% |